C. Cantillon

When should patients with lethal ventricular arrhythmia resume driving? An analysis of state regulations and physician practices.

S. Strickberger, P. Friedman, C. Cantillon, 1991, Annals of internal medicine.

Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent.

E. Antman, L. Hartley, R. Kelly, 1990, Circulation.

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.

E. Antman, P. Friedman, S. Reimold, 1993, The American journal of cardiology.

Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.

E. Antman, P. Friedman, C. Cantillon, 1990, Journal of the American College of Cardiology.

Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter.

E. Antman, P. Friedman, C. Cantillon, 1988, Journal of the American College of Cardiology.

Risk factors for the development of recurrent atrial fibrillation: role of pacing and clinical variables.

G. Lamas, E. Antman, S. Reimold, 1995, American heart journal.

Comparison of effects of propranolol versus pindolol on sinus rate and pacing frequency in sick sinus syndrome.

G. Lamas, E. Antman, R. Fish, 1993, The American journal of cardiology.

Efficacy of intravenous propafenone for the acute management of atrial fibrillation.

E. Antman, J. Vita, P. Friedman, 1989, The American journal of cardiology.